Siliq Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of moderate to severe plaque psoriasis, limited efficacy of conventional systemic therapies, growing dermatologist adoption of biologics, expansion of specialty dermatology clinics, improved diagnosis rates.

The growth in the forecast period can be attributed to increasing demand for next-generation biologics, rising focus on long-term disease management, expansion of personalized immunology treatments, growing investments in inflammatory disease research, increasing patient access to specialty therapies. Major trends in the forecast period include increasing adoption of targeted biologic therapies, growing use of il-17 pathway inhibitors, rising focus on personalized psoriasis treatment, expansion of specialty pharmacy distribution, enhanced monitoring of treatment outcomes.

The increase in the prevalence of skin diseases is expected to drive the growth of the Siliq market in the future. Skin disease encompasses a wide range of conditions that affect the skin's structure, function, or appearance, often caused by infections, inflammation, genetic factors, autoimmune disorders, or environmental influences. Factors contributing to the rising prevalence of skin diseases include environmental changes, increasing pollution levels, greater sun exposure, genetic predispositions, and lifestyle factors such as poor diet and stress. Siliq is particularly beneficial for treating moderate to severe plaque psoriasis, as it targets specific immune system pathways to reduce inflammation, improve skin appearance, and alleviate symptoms like redness, scaling, and itching. For example, in January 2024, the American Cancer Society, a U.S.-based non-profit organization, projected 108,270 reported cases of skin cancer, a 3.2% increase from the 104,930 cases in 2023. As a result, the growing prevalence of skin diseases is fueling the growth of the Siliq market.

The increasing geriatric population is expected to drive the growth of the Siliq market in the coming years. The geriatric population typically refers to individuals aged 65 and older, although this threshold may vary depending on the context or healthcare standards. The rise in the geriatric population is attributed to longer life expectancies, advancements in healthcare, and declining birth rates, resulting in a larger proportion of older individuals worldwide. Siliq is particularly beneficial for the geriatric population, as it offers an effective treatment option for moderate to severe plaque psoriasis, helping manage symptoms and improve skin health in older adults who may have limited treatment options due to age-related health issues. For example, in July 2024, the UK Parliament's House of Commons Library reported that in 2022, the UK had 12.7 million individuals aged 65 and above, making up 19% of the total population. This number is expected to rise to 22.1 million, or 27% of the population, by 2072. As a result, the growing geriatric population is anticipated to fuel the continued growth of the Siliq market.

The growing focus on precision medicine is also expected to boost the Siliq market. Precision medicine refers to a personalized healthcare approach that tailors treatments based on an individual's genetic, environmental, and lifestyle factors. The rising emphasis on precision medicine is driven by advancements in genetic research, a better understanding of personalized treatments, and the potential for improved patient outcomes through targeted therapies. Siliq aligns with this trend by providing targeted treatment for moderate to severe plaque psoriasis by specifically inhibiting the IL-17A pathway, enabling more personalized and effective therapy for individual patients. For instance, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare diseases, up from just six approvals in 2022. Therefore, the growing emphasis on precision medicine is expected to drive continued growth in the Siliq market.

Major companies operating in the siliq market are Valeant Pharmaceuticals International Inc.

North America was the largest region in the siliq market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the siliq market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the siliq market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the siliq market by increasing costs of imported monoclonal antibody production inputs, specialized bioprocessing equipment, packaging materials, and cold-chain logistics services. North America and Europe are most affected due to reliance on global biologics manufacturing networks, while Asia-Pacific faces elevated costs in export-oriented biologic production. These tariffs are contributing to higher therapy costs and distribution challenges for specialty pharmacies. At the same time, they are encouraging domestic biologics manufacturing, regional fill-finish expansion, and investments in localized supply chains for immunology therapies.

The siliq market research report is one of a series of new reports that provides siliq market statistics, including siliq industry global market size, regional shares, competitors with a siliq market share, detailed siliq market segments, market trends and opportunities, and any further data you may need to thrive in the siliq industry. This siliq market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Siliq is a prescription medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Its mechanism of action involves targeting and inhibiting the IL-17A receptor. IL-17A is a pro-inflammatory cytokine that plays a key role in the development of inflammation in conditions like plaque psoriasis.

The primary clinical indications for Siliq include moderate-to-severe plaque psoriasis and other related conditions. Moderate to severe plaque psoriasis is a chronic skin disorder characterized by red, inflamed patches covered with silvery-white scales. Siliq, a biologic therapy, is specifically designed to treat moderate to severe plaque psoriasis by targeting and inhibiting the interleukin-17A receptor, which helps to reduce inflammation and plaque formation in affected patients. The medication is distributed through various channels, including hospital pharmacies, retail pharmacies, and specialty pharmacies, with end users including hospitals, specialty clinics, and home care settings.

The siliq market consists of sales of single-dose prefilled syringes and single-dose prefilled autoinjectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.